Theseus Pharmaceuticals Inc   (THRX)
Other Ticker:  
Price: $3.7800 $0.06 1.613%
Day's High: $3.82 Week Perf: 9.57 %
Day's Low: $ 3.68 30 Day Perf: 63.64 %
Volume (M): 575 52 Wk High: $ 14.77
Volume (M$): $ 2,172 52 Wk Avg: $6.78
Open: $3.76 52 Wk Low: $2.05

 Market Capitalization (Millions $) 166
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -57
 Cash Flow (TTM) (Millions $) -198
 Capital Exp. (TTM) (Millions $) 1

Theseus Pharmaceuticals Inc
Theseus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, USA. It specializes in developing innovative immunotherapy treatments for cancer patients. Founded in 2016, the company is led by an experienced management team, including Dr. John C. Reed, MD, PhD, as the CEO and Dr. Frank Nestle, MD, PhD, as the Chief Scientific Officer.

Theseus Pharmaceuticals' pipeline focuses on immune cell therapies that target solid tumors. Its lead product candidate, ThNK-1, is a CAR-T (Chimeric Antigen Receptor T-cell) therapy that targets the protein CD73, which is highly expressed in various cancer cells. ThNK-1 is in Phase 1 clinical trials for the treatment of advanced solid tumors.

The company also has several other preclinical programs in development, including TNK-2, a dual-targeting CAR-T therapy for the treatment of solid tumors, and TNK-3, a TCR (T-cell receptor) therapy for targeting solid tumors with neoantigens.

Theseus Pharmaceuticals has received significant funding from reputable sources. It has raised more than $120 million in various rounds of financing from investors, including Canaan Partners, 6 Dimensions Capital, Morningside Ventures, and Parian Global Management.

The company collaborates with prominent research institutions and biopharmaceutical companies to advance its technologies. Theseus has strategic partnerships with the University of British Columbia and Novartis for the development and commercialization of its CAR-T and TCR therapies.

Overall, Theseus Pharmaceuticals is a promising biotechnology company that aims to improve cancer treatment options through innovative immunotherapies. Its strong management team, well-funded pipeline, and strategic partnerships are likely to continue to drive its growth in the coming years.

   Company Address: 314 Main Street Cambridge 2142 MA
   Company Phone Number: 400-9491   Stock Exchange / Ticker: NASDAQ THRX
   THRX is expected to report next financial results on March 08, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Lipocine Inc

the Major Pharmaceutical Preparations company in the fiscal time-frame ending September 30 2023

In its most recent fiscal period Lipocine Inc increased a shortfall per share at $-1.27 per share, opposite of $-0.03 per share a year before reporting season, In the prior reporting season LPCN realized $-0.68 per share.

Bioxytran Inc

Bioxytran Inc Faces Investor Concerns as Operating Deficit Grows in Q3 2023

Following the recent announcement of operating deficit for the third quarter of 2023, Bioxytran Inc, a major player in the pharmaceutical preparations industry, has captured investors' attention. The company's financial performance has raised questions about its ability to generate revenue in the near future.
For the third quarter of 2023, Bioxytran Inc reported an operating deficit of $-0.985464 million. This represents a worsening of the deficit compared to the same period in 2022, where it stood at $0.014225 million. However, the main concern for investors lies in the absence of any reported revenue during this time frame.

Briacell Therapeutics Corp

Briacell Therapeutics Corp Releases Fourth Quarter Fiscal Results - Showcasing Impressive Growth in Major Pharmaceutical Preparations Sector

The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.

Gt Biopharma Inc

GTBP Reports Impressive Operating Surplus of $3.122 Million in Third Quarter Earnings Season

The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com